KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBT (2017 - 2026)

Amneal Pharmaceuticals has reported EBT over the past 9 years, most recently at $55.2 million for Q4 2025.

  • For Q4 2025, EBT rose 460.57% year-over-year to $55.2 million; the TTM value through Dec 2025 reached $139.2 million, up 353.05%, while the annual FY2025 figure was $139.2 million, 353.05% up from the prior year.
  • EBT for Q4 2025 was $55.2 million at Amneal Pharmaceuticals, up from -$5.2 million in the prior quarter.
  • Over five years, EBT peaked at $55.2 million in Q4 2025 and troughed at -$232.7 million in Q2 2022.
  • A 5-year average of -$8.6 million and a median of $68500.0 in 2021 define the central range for EBT.
  • On a YoY basis, EBT climbed as much as 953.07% in 2023 and fell as far as 990.28% in 2023.
  • Year by year, EBT stood at -$16.3 million in 2021, then skyrocketed by 53.09% to -$7.7 million in 2022, then tumbled by 990.28% to -$83.5 million in 2023, then soared by 81.65% to -$15.3 million in 2024, then soared by 460.57% to $55.2 million in 2025.
  • Business Quant data shows EBT for AMRX at $55.2 million in Q4 2025, -$5.2 million in Q3 2025, and $51.7 million in Q2 2025.